Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.42 |
| ▸ | OTC | P00480 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | NPY4R | P50391 | 9/20 | 0.40 |
| ▸ | NPY1R | P25929 | 6/20 | 0.40 |
| ▸ | NPY2R | P49146 | 4/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.39 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.37 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.37 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5158398 | 1.00 | DPP7 (0.42) | DPP7OTCALOX15NPY4RNPY1R | |
| SCHEMBL30256813 | 1.00 | DPP7 (0.42) | DPP7OTCALOX15NPY4RNPY1R | |
| SCHEMBL598710 | 1.00 | DPP7 (0.42) | DPP7OTCALOX15NPY4RNPY1R | |
| Hydrochloric Acid SCHEMBL1897057 | 0.98 | DPP7 (0.41) | DPP7OTCALOX15NPY4RNPY1R | |
| Hydrochloric Acid SCHEMBL118624 | 0.98 | DPP7 (0.41) | DPP7OTCALOX15NPY4RNPY1R | |
| Hydrochloric Acid SCHEMBL123461 | 0.98 | DPP7 (0.41) | DPP7OTCALOX15NPY4RNPY1R | |
| Hydrochloric Acid SCHEMBL14831575 | 0.98 | DPP7 (0.41) | DPP7OTCALOX15NPY4RNPY1R | |
| Hydrochloric Acid SCHEMBL29400705 | 0.98 | DPP7 (0.41) | DPP7OTCALOX15NPY4RNPY1R | |
| Bromide SCHEMBL9279144 | 0.98 | DPP7 (0.41) | DPP7OTCALOX15NPY4RNPY1R | |
| Hydrochloric Acid SCHEMBL7583819 | 0.98 | DPP7 (0.41) | DPP7OTCALOX15NPY4RNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1455 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121851107-B | Aromatic acid salt of apolipoprotein E mimic peptide, and preparation method and medical application thereof | 中国药科大学 | 2026-05-15 | — | — | CN | claimed |
| EP-4022090-B1 | COMPOSITIONS FOR USE IN METHODS FOR REDUCING THE RISK OF DEVELOPING AND FOR TREATING CANINE HYPOTHYROIDISM | HILLS PET NUTRITION INC (US) | 2026-03-18 | — | — | EP | claimed |
| US-20260027071-A1 | COMPOSITION FOR PROMOTING COLLAGEN PRODUCTION COMPRISING AMIDATED AMINO ACID | KYUNGPOOK NAT UNIV IND ACADEMIC COOP FOUND (KR) | 2026-01-29 | — | — | US | claimed |
| EP-4638785-A1 | A PCR-ELISA ANALOGOUS ANTIBODY-FREE METHOD FOR DETECTING A TARGET NUCLEIC ACID IN A SAMPLE | Universität Heidelberg (DE) | 2025-10-29 | — | — | EP | claimed |
| EP-4622966-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | Radionetics Oncology, Inc. (US) | 2025-10-01 | — | — | EP | claimed |
| US-20250255803-A1 | INSULIN PREPARATIONS CONTAINING METHIONINE | SANOFI AVENTIS DEUTSCHLAND (DE) | 2025-08-14 | — | — | US | claimed |
| CN-116023432-B | Bissialoganglioside GD2 affinity peptide and application thereof | 中国药科大学 | 2025-06-03 | — | — | CN | claimed |
| CN-120022230-A | Peroxide hydrogel and preparation method thereof | 千氧生物技术(上海)有限公司 | 2025-05-23 | — | — | CN | claimed |
| CN-119894503-A | Lipid Nanoparticle (LNP) compositions or formulations for nucleic acid therapy | 波珀瓦克斯私人有限公司 | 2025-04-25 | — | — | CN | claimed |
| WO-2025043394-A1 | KIT FOR FORMING SUPRAMOLECULAR SELF-ASSEMBLY COMPLEX AND USE THEREOF | 北京睿创康泰医药研究院有限公司 | 2025-03-06 | — | — | WO | claimed |
| EP-0473700-A1 | AN ENZYME-CATALYZED PROCESS FOR PREPARING N-ACYL AMINO ACIDS AND N-ACYL AMINO ACID AMIDES | NOVO NORDISK A/S (DK) | 1992-03-11 | — | — | EP | claimed |
| EP-0193113-B1 | PROCESS FOR OPTICALLY ISOMERIZING OPTICALLY ACTIVE ALPHA-AMINO ACID AMIDES AND PROCESS FOR PRODUCING OPTICALLY ACTIVE ALPHA-AMINO ACIDS | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 1992-01-22 | — | — | EP | claimed |
| EP-0301970-B1 | METHOD FOR DISSOLVING ARGININEAMIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MITSUBISHI KASEI CORPORATION (JP) | 1991-11-21 | — | — | EP | claimed |
| CN-1051770-A | The aramid fiber of deposit-free finish | DU PONT (US) | 1991-05-29 | — | — | CN | claimed |
| WO-1990014429-A1 | AN ENZYME-CATALYZED PROCESS FOR PREPARING N-ACYL AMINO ACIDS AND N-ACYL AMINO ACID AMIDES | NOVO NORDISK A/S (DK) | 1990-11-29 | — | — | WO | claimed |
| US-4918196-A | HEATING IN PRESENCE OF STRONG BASE, SOLVENT OR SOLVENT-FREE | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 1990-04-17 | — | — | US | claimed |
| EP-0301970-A1 | Method for dissolving arginineamides and pharmaceutical compositions containing them | MITSUBISHI KASEI CORPORATION (JP) | 1989-02-01 | — | — | EP | claimed |
| EP-0071926-B1 | NEW RIBOFURANURONIC ACID DERIVATIVES, PROCESSES FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-10-08 | — | — | EP | claimed |
| EP-0193113-A1 | Process for optically isomerizing optically active alpha-amino acid amides and process for producing optically active alpha-amino acids | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 1986-09-03 | — | — | EP | claimed |
| EP-0071926-A1 | New ribofuranuronic acid derivatives, processes for preparation thereof and pharmaceutical compositions thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-02-16 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027071-A1 | COMPOSITION FOR PROMOTING COLLAGEN PRODUCTION COMPRISING AMIDATED AMINO ACID | COL2A1, COL14A1, GLS | DPP7 1389/4885OTC 478/4885ALOX15 2921/4885 |
| US-20250255803-A1 | INSULIN PREPARATIONS CONTAINING METHIONINE | IAPP, INSR, INSRR | DPP7 177/4885OTC 281/4885ALOX15 2011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.